Abstract:Protein Arginine Methyltransferases (PRMTs) are a family of enzymes regulating protein arginine methylation, which is a post-translational modification crucial for various cellular processes. Recent studies have highlighted the mechanistic role of PRMTs in cancer pathogenesis, immunotherapy, and drug resistance. PRMTs are involved in diverse oncogenic processes, including cell proliferation, apoptosis, and metastasis. They exert their effects by methylation of histones, transcription factors, and other regulatory proteins, resulting in altered gene expression patterns. PRMT-mediated histone methylation can lead to aberrant chromatin remodeling and epigenetic changes that drive oncogenesis. Additionally, PRMTs can directly interact with key signaling pathways involved in cancer progression, such as the PI3K/Akt and MAPK pathways, thereby modulating cell survival and proliferation. In the context of cancer immunotherapy, PRMTs have emerged as critical regulators of immune responses. They modulate immune checkpoint molecules, including programmed cell death protein 1 (PD-1), through arginine methylation. Drug resistance is a significant challenge in cancer treatment, and PRMTs have been implicated in this phenomenon. PRMTs can contribute to drug resistance through multiple mechanisms, including the epigenetic regulation of drug efflux pumps, altered DNA damage repair, and modulation of cell survival pathways. In conclusion, PRMTs play critical roles in cancer pathogenesis, immunotherapy, and drug resistance. In this overview, we have endeavored to illuminate the mechanistic intricacies of PRMT-mediated processes. Shedding light on these aspects will offer valuable insights into the fundamental biology of cancer and establish PRMTs as promising therapeutic targets.

Protein Arginine Methyltransferases (PRMTs): Orchestrators of Cancer Pathogenesis, Immunotherapy Dynamics, and Drug Resistance

PRMT1 in human neoplasm: cancer biology and potential therapeutic target

Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance

The Role of PRMT1 in Cellular Regulation and Disease: Insights into Biochemical Functions and Emerging Inhibitors for Cancer Therapy

Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy

Overview of PRMT1 modulators: Inhibitors and degraders

Protein arginine methyltransferases: promising targets for cancer therapy

Dysregulation of arginine methylation in tumorigenesis

Research progress on PRMTs involved in epigenetic modification and tumour signalling pathway regulation (Review)

PRMT1 Is Recruited via DNA-PK to Chromatin Where It Sustains the Senescence-Associated Secretory Phenotype in Response to Cisplatin

Protein arginine methylation of non-histone proteins and its role in diseases.

The role of protein arginine methylation 5 in DNA damage repair and cancer therapy

The Emerging Role of PRMT6 in Cancer

The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond

Overview of the PRMT6 modulators in cancer treatment: Current progress and emerged opportunity

PRMT5 function and targeting in cancer

The Role of PRMT5 in Immuno-Oncology

PRMT5 activates AKT via methylation to promote tumor metastasis

Proteomics Profiling of Arginine Methylation Defines PRMT5 Substrate Specificity

PRMT5: a putative oncogene and therapeutic target in prostate cancer

Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies